Valo Health

What Valo Health does

Valo Health is a private, clinical-stage biopharmaceutical technology company founded in 2019 by Flagship Pioneering and headquartered in Boston, Massachusetts. It builds and operates the Opal Computational Platform, an integrated, cloud-based, end-to-end drug discovery and development engine that combines AI/machine learning, advanced causal inference, statistical genetics, geometric deep learning on molecular graphs, and closed-loop generative chemistry. The platform is fed by an exclusive longitudinal human dataset spanning more than 125 million patient-years and 17+ million de-identified patient records, augmented by an exclusive partnership with Global Genomics Group covering the world's largest cardio-metabolic dataset, and is paired with human tissue validation capabilities acquired through TARA Biosystems.

The company pursues a hybrid business model: it advances an internal pipeline of therapeutic candidates (most notably OPL-0401 in Phase 2 for non-proliferative diabetic retinopathy, and the OPL-0101 oncology candidate from the Courier Therapeutics acquisition) while monetizing the platform primarily through enterprise B2B collaborations with large pharmaceutical companies, including a $3 billion-plus milestone-valued partnership with Merck KGaA in Parkinson's disease and an expanded Novo Nordisk collaboration covering up to 20 drug programs in cardiometabolic disease with $190 million in near-term payments. Revenue mechanics combine upfront payments, milestone payments, and royalties on partnered programs, plus co-development arrangements with Charles River (Logica), Pfizer (via Pioneering Medicines), and Lundbeck. The company employs 101-250 staff across offices in Boston, Lexington, New York, San Francisco, Branford (CT), and Tel Aviv.

Name

Valo Health

Legal name

Valo Health, Inc.

Website

https://valohealth.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

Valo Health is a private Boston-based biopharma technology company that uses its Opal Computational Platform — combining AI, causal inference, and 125+ million patient-years of human data — to discover and develop therapeutics in cardiometabolic, oncology, and neurodegenerative disease, monetizing via enterprise partnerships and an internal pipeline.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Computational drug development
• Small molecule therapeutics
• Pharmaceutical partnerships
• Human causal biology

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Partnerships: Valo partners with pharmaceutical companies where partners lead clinical development while Valo retains royalties and uses success-based economics. Collaborations include upfront payments, milestone payments, and royalties on successful drug development.
2. Collaboration Payments: Major collaboration with Merck KGaA valued at over $3 billion in upfront and potential milestone payments for Parkinson's disease drug discovery.
3. Novo Nordisk Partnership: Expanded partnership with Novo Nordisk includes $190 million near-term payments for obesity, type 2 diabetes, and cardiovascular disease programs, with up to 20 drug programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Valo Health operates the Opal Computational Platform, an integrated, cloud-based, end-to-end drug discovery and development engine that combines machine learning, AI, advanced causal inference techniques, and predictive chemistry with large-scale human data. The platform identifies novel disease targets and engineers small molecules across cardiovascular metabolic renal, oncology, and neurodegenerative disease areas. Valo monetizes through enterprise partnerships with pharmaceutical and biotech companies, retaining royalties and milestone rights while partners lead clinical development.

Product overview

Valo Health operates as a technology company offering the Opal Computational Platform™ as its core AI-driven drug discovery and development engine. The platform combines real-world patient data, AI, causal inference techniques, and predictive chemistry into an integrated system. Supporting the platform, Valo offers Logica® (an AI-powered drug discovery solution developed with Charles River Laboratories), and maintains an internal pipeline of therapeutic candidates including OPL-0401 (Phase 2 for diabetic retinopathy) and OPL-0101 (IND-enabling stage for cancer immunotherapy). The platform enables identification of novel disease targets, rapid small molecule engineering, and validation in human tissue across cardiovascular metabolic renal, oncology, and neurodegenerative disease areas.

Differentiator

Problem solved

Functional benefit

Brands

• Opal Computational Platform: First-of-its-kind, end-to-end drug development platform integrating machine learning, cloud computing, and human-centric data for accelerated drug discovery and development.

Products and services

• Opal Computational Platform An integrated, end-to-end drug discovery and development platform that combines AI/machine learning, causal inference techniques, predictive chemistry, and human-centric data to identify disease targets and engineer novel small molecules. For pharmaceutical and biotechnology enterprise partners.
• Logica An AI-powered drug discovery solution developed in partnership with Charles River Laboratories that integrates computational capabilities with preclinical laboratory services to rapidly deliver optimized drug candidates. For pharmaceutical partners seeking preclinical candidate generation.
• OPL-0401 An oral ROCK1/2 inhibitor in Phase 2 clinical development for the treatment of Non-Proliferative Diabetic Retinopathy, demonstrating the company's ability to advance internally developed therapeutic candidates.
• OPL-0101 (formerly CT-101) A fusion protein agonist acquired through the Courier Therapeutics acquisition, targeting both natural killer cells and CD8+ cytotoxic T cells for cancer immunotherapy applications including colon cancer, non-small cell lung cancer, renal cell carcinoma, and melanoma.
• Oncology Therapeutic Programs Pipeline of preclinical oncology candidates including NAMPT (synthetic lethal cancer metabolism), PARP1 (brain metastases and glioblastoma), USP28 (c-Myc driven cancers), and HDAC3 (first-in-class synthetic lethality approach) programs.

Quantifiable outcome

• Potentially half the time and cost for drug development with fewer failures
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and major.

• Merck KGaAcoreStrategic or Co-development Partner · 20 November 2025Strategic collaboration to discover and develop novel treatments for Parkinson's disease and related neurodegenerative disorders. Valo leverages its AI-enabled human data platforms and discovery capabilities while Merck KGaA contributes neurology research expertise. Partnership valued at over $3 billion in upfront and potential milestone payments.
• The Michael J. Fox FoundationmajorStrategic or Co-development Partner · 9 September 2025Grant from the foundation to advance Parkinson's disease research. Focus on advancing understanding of NOD2, associated with increased risk of PD, as part of the foundation's Targets to Therapies Initiative.
• PfizercoreStrategic or Co-development Partner · 1 April 2025Agreement between Pioneering Medicines and Pfizer to discover potential novel, selective inhibitors for autoimmune disease. Combines Pfizer's clinical development capabilities with Valo's AI-driven discovery platform.
• Charles River LaboratoriescoreStrategic or Co-development Partner · 25 March 2025Partnership through Pioneering Medicines using Logica AI-powered drug discovery platform. Successfully identified a potential therapeutic for lupus. Charles River provides preclinical CRO services integrated with Valo's AI capabilities.
• nferencemajorTechnology or Integration · 18 March 2025Long-term partnership to accelerate human-centric drug discovery and development. Combines nference's AI and real-world data capabilities with Valo's Opal Computational Platform.
• Novo NordiskcoreStrategic or Co-development Partner · 8 January 2025Expanded collaboration to discover and develop novel treatments for cardiometabolic diseases. Initial agreement signed in 2023, expanded in early 2025 to develop up to twenty drug programs in obesity, type 2 diabetes, and cardiovascular disease. Valo receives $190 million in near-term payments.
• KSM Research and Innovation CentermajorStrategic or Co-development Partner · 19 September 2022First-of-its-kind multiyear collaboration leveraging KSM's biobank, the largest in Israel and one of the most comprehensive globally with over 800,000 de-identified biological samples. Joint research to identify preventive care and personalized medicine insights.
• Global Genomics Group (G3)coreTechnology or Integration · 22 December 2020Exclusive partnership providing access to the world's largest and most detailed cardio-metabolic dataset. G3's GLOBAL study includes nearly 8,000 patients with 3 billion data points each. Valo has identified six validated targets and approximately 20 early potential targets through this partnership.
• LundbeckmajorStrategic or Co-development PartnerPartnership to discover novel drugs for neurological disease using AI-powered platform capabilities. Combines Lundbeck's neuroscience expertise with Valo's computational discovery capabilities.
• Pioneering MedicinescoreStrategic or Co-development PartnerInternal Flagship Pioneering unit that serves as a strategic partner, utilizing Valo's Opal platform for multiple therapeutic programs across different disease areas.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Exscientia: Exscientia is an AI-driven drug discovery company that combines automated chemistry, active learning, and human tissue validation to design small-molecule candidates. Like Valo, it signs major pharma partnerships (e.g., Sanofi, Bristol-Myers Squibb) and advances an internal pipeline, placing it in direct competition for similar deal flow.
• Insitro: Insitro uses ML combined with high-throughput cellular data to discover therapeutics, particularly in metabolic and neurodegenerative disease. Its partnership-heavy model with Gilead, Bristol-Myers Squibb, and Eli Lilly mirrors Valo's enterprise pharma GTM, and both compete for similar AI-discovery talent and deals.
• Isomorphic Labs: Isomorphic Labs is Alphabet/DeepMind's drug discovery spinout applying AlphaFold-derived AI to small-molecule design. It has signed large multi-target pharma deals (Eli Lilly, Novartis) and competes head-to-head with Valo for the attention and R&D budgets of big pharma partners.
• Atomwise: Atomwise pioneered AtomNet, a deep-learning platform for structure-based small molecule design, and has partnered with pharma and academic groups worldwide. Valo even hired its former Principal Scientist of Cheminformatics (Andrea Rossi), illustrating the tight talent and technology overlap between the two platforms.
• XtalPi: XtalPi combines AI, physics-based modeling, and robotic automation to accelerate small-molecule and crystalline drug design. It serves global pharma clients (including Pfizer as an investor) and operates an internal pipeline, making it a direct competitor for AI drug discovery partnerships.
• Benevolent AI: Benevolent AI applies knowledge graphs and ML to biomedical literature and multi-omics data for target discovery, with internal programs in neurodegeneration, immunology, and rare disease. It overlaps with Valo in the human-data-plus-causal-AI approach to target identification and in pharma partnerships.
• Recursion Pharmaceuticals: Recursion is a direct competitor using AI/ML and high-throughput biology to discover and develop therapeutics across multiple disease areas. Like Valo, it pursues both internal pipeline programs and large pharma partnerships (e.g., Roche/Genentech, Bayer) and emphasizes end-to-end integration of data, computation, and experimentation.
• Schrödinger: Schrödinger operates a physics-based computational platform for molecular design and is one of the most established AI-driven drug discovery players. It competes with Valo for pharma software/platform deals (e.g., with major pharma partners) and runs its own pipeline, making it a closely comparable business model.

Broad incumbents

• Charles River Laboratories: Charles River is both a Valo partner (via the Logica AI platform) and a broader preclinical CRO incumbent. It offers adjacent services across the drug discovery value chain (in vivo, in vitro, safety, manufacturing) that overlap with portions of Valo's vertically integrated discovery offering.

Emerging players

• Ginkgo Bioworks: Ginkgo applies an AI-enabled organism engineering platform to synthetic biology and biopharma programs. While its core focus is cell engineering rather than small-molecule drug discovery, it competes for similar pharma data-and-platform partnership budgets and serves as a comparable platform-economy model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/valohealth
• LinkedInlinkedin.com/company/valo-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valo Health